Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Protocol No
SWOG-S1608
Principal Investigator
Timothy Fenske
Phase
II
Summary
The purpose of this study is to compare any good and bad effects of using different drugs in combination with an antibody. An antibody is a protein that can recognize and attack foreign objects (antigens) in the body. Here, the antibody is obinutuzumab. It is looking for CD20, an antigen that is found on tumor cells.
Description
Randomized Phase II Trial in Early Relapsing Or Refractory Follicular Lymphoma
Participating Institutions
Froedtert Hospital
Status
SUSPENDED
Share This: